relebactam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 5342 1174018-99-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • recarbrio
  • relebactam
RECARBRIO is a combination of imipenem/cilastatin and relebactam. Imipenem is a penem antibacterial drug, cilastatin sodium is a renal dehydropeptidase inhibitor, and relebactam is a beta lactamase inhibitor. Cilastatin limits the renal metabolism of imipenem and does not have antibacterial activity. The bactericidal activity of imipenem results from binding to PBP 2 and PBP 1B in Enterobacteriaceae and Pseudomonas aeruginosa and the subsequent inhibition of penicillin binding proteins (PBPs). Inhibition of PBPs leads to the disruption of bacterial cell wall synthesis. Imipenem is stable in the presence of some beta lactamases. Relebactam has no intrinsic antibacterial activity. Relebactam protects imipenem from degradation by certain serine beta lactamases such as Sulhydryl Variable (SHV), Temoneira (TEM), Cefotaximase-Munich 13 Reference ID: 4462927 (CTX-M), Enterobacter cloacae P99 (P99), Pseudomonas-derived cephalosporinase (PDC), and Klebsiella-pneumoniae carbapenemase (KPC)
  • Molecular weight: 348.37
  • Formula: C12H20N4O6S
  • CLOGP: -1.75
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 3
  • TPSA: 128.28
  • ALOGS: -2.08
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 16, 2019 FDA MSD MERCK CO

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DH56 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Carbapenems
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pyelonephritis indication 45816000 DOID:11400
Urinary tract infectious disease indication 68566005
Intestinal infection due to Pseudomonas indication 82930004
Intestinal infection due to E. coli indication 111839008
Infectious disease of abdomen indication 128070006
Pseudomonas gastrointestinal tract infection indication 266078006
Escherichia coli urinary tract infection indication 301011002
Pseudomonas urinary tract infection indication 301013004
Gastrointestinal infection caused by Klebsiella aerogenes indication 421429008
Complicated Genitourinary Tract Infection indication
Urinary tract infection caused by Klebsiella indication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.53 acidic
pKa2 9.75 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-lactamase Enzyme INHIBITOR IC50 6.40 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-lactamase Enzyme INHIBITOR IC50 6.33 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-lactamase Enzyme INHIBITOR IC50 6.64 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-lactamase Enzyme INHIBITOR IC50 6.59 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-lactamase Enzyme INHIBITOR IC50 6.04 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
1174020-13-3 SECONDARY_CAS_RN
4039070 VANDF
C5196210 UMLSCUI
CHEMBL3301605 ChEMBL_ID
CHEMBL3112741 ChEMBL_ID
D11621 KEGG_DRUG
DB12377 DRUGBANK_ID
10852 IUPHAR_LIGAND_ID
C000633884 MESH_SUPPLEMENTAL_RECORD_UI
C568736 MESH_SUPPLEMENTAL_RECORD_UI
Y1MYA2UHFL UNII
44129647 PUBCHEM_CID
2184137 RXNORM
321713 MMSL
37333 MMSL
d09357 MMSL
018062 NDDF
789066008 SNOMEDCT_US

Pharmaceutical products:

None